Pharvaris N.V. (PHVS)
| Market Cap | 1.85B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -206.29M |
| Shares Out | 65.41M |
| EPS (ttm) | -3.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 307,243 |
| Open | 28.90 |
| Previous Close | 28.71 |
| Day's Range | 28.01 - 29.43 |
| 52-Week Range | 14.59 - 30.24 |
| Beta | -2.58 |
| Analysts | Buy |
| Price Target | 41.82 (+48.19%) |
| Earnings Date | May 12, 2026 |
About PHVS
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE a... [Read more]
Analyst Forecast
According to 11 analysts, the average rating for PHVS stock is "Buy." The 12-month stock price target is $41.82, which is an increase of 48.19% from the latest price.
News
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet ne...
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
ZUG, Switzerland, April 02, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet ne...
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
ZUG, Switzerland, March 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet ne...
Pharvaris Transcript: Leerink Global Healthcare Conference 2026
Strong RAPIDe-3 data supports NDA filing for acute HAE in H1, with prophy trial readout expected in Q3. Oral deucrictibant offers rapid symptom relief and unique flexibility for both on-demand and prophylactic use, positioning it well in a dynamic, growing market.
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
ZUG, Switzerland, March 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet ne...
Pharvaris Transcript: The Citizens Life Sciences Conference 2026
The company is advancing oral therapies for hereditary and acquired angioedema, with strong phase III data for on-demand treatment and promising phase II results for prophylaxis. NDA filings and launches are planned, supported by a robust cash position and commercial infrastructure.
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
ZUG, Switzerland, March 02, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet ne...
Pharvaris Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The company is advancing an oral therapy for HAE, with phase III data showing rapid, robust efficacy in on-demand use and promising results in prophylaxis. NDA filing is planned for the first half of the year, with a strong cash runway and multiple data presentations at AAAAI.
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting
Pivotal Phase 3 data from RAPIDe-3 of deucrictibant for the on-demand treatment of HAE attacks to be presented for the first time Pivotal Phase 3 data from RAPIDe-3 of deucrictibant for the on-demand ...
Pharvaris Outlines 2026 Strategic Priorities
Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026 Preparation of NDA dossier of deucrictibant for on-demand treatment of HA...
Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows
Pharvaris N.V. (NASDAQ: PHVS) on Wednesday shared topline data from the RAPIDe-3 Phase 3 trial of deucrictibant for the on-demand treatment of hereditary angioedema (HAE) attacks.
Pharvaris Transcript: Study Update
RAPIDe-3 phase III results show deucrictibant immediate release capsule achieved rapid and durable symptom relief for HAE attacks, meeting all primary and secondary endpoints with a favorable safety profile. The study included a diverse, global population and all HAE subtypes, supporting broad applicability and strong patient interest in oral therapy.
Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks
Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p
Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update
Topline data for RAPIDe-3, a pivotal Phase 3 study of deucrictibant immediate-release capsule for the on-demand treatment of HAE attacks, expected in 4Q2025 Enrollment in CHAPTER-3, a pivotal Phase 3 ...
Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting
ZUG, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet nee...
Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting
ZUG, Switzerland, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet nee...
Pharvaris Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Deucrictibant aims to address unmet needs in hereditary angioedema with oral, highly efficacious, and well-tolerated formulations for both on-demand and prophylactic use. Phase 3 trials are progressing ahead of schedule, with strong financial positioning and plans for label expansion into broader angioedema indications.
Pharvaris Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Two pivotal Phase 3 studies for deucrictibant in hereditary angioedema are expected to read out by 2026, with a Phase 3 in acquired angioedema starting this year. Phase II data show rapid symptom relief and strong attack reduction, supporting a dual oral formulation strategy for both on-demand and prophylactic use.
Pharvaris Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
Phase 3 data for two oral HAE therapies are expected by end of 2024 and 2026, targeting both on-demand and prophylactic markets. Oral options are poised to capture significant share from injectables, with a focus on efficacy, convenience, and a broader label. U.S. launch is prioritized, with ex-U.S. partnerships under consideration.
Pharvaris Transcript: Cantor Global Healthcare Conference 2025
Deucrictibant is positioned as a leading oral therapy for both on-demand and prophylactic use in bradykinin-mediated angioedema, with pivotal data expected in Q4 and a US launch targeted for early 2027. The company is expanding its clinical program and commercial preparations, aiming for broad market impact and differentiation through unique B2 receptor targeting.
Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update
Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in 4Q2025 Enrollment continues in CHAPTER-3, a pivotal Phase 3 study of deuc...
Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to addr...
Pharvaris Announces Proposed Public Offering of Ordinary Shares
ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to addr...
Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025
ZUG, Switzerland, July 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of...
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet nee...